Wang, Chun Jing
Petersone, Lina http://orcid.org/0000-0001-8571-9185
Edner, Natalie M. http://orcid.org/0000-0003-2799-2890
Heuts, Frank
Ovcinnikovs, Vitalijs
Ntavli, Elisavet
Kogimtzis, Alexandros
Fabri, Astrid
Elfaki, Yassin http://orcid.org/0000-0001-6628-3080
Houghton, Luke P.
Hosse, Ralf J.
Schubert, David A.
Frei, Andreas P. http://orcid.org/0000-0002-9996-8251
Ross, Ellen M. http://orcid.org/0000-0001-9249-1043
Walker, Lucy S. K. http://orcid.org/0000-0001-5986-5015
Funding for this research was provided by:
Diabetes UK (20/0006172)
RCUK | Medical Research Council (MR/N001435/1)
Rosetrees Trust (A1992)
Article History
Received: 9 November 2021
Accepted: 26 October 2022
First Online: 9 November 2022
Change Date: 15 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-41483-4
Competing interests
: R.J.H., D.A.S. and A.Fr. declare interests in developing IL-2 therapeutics at Roche. R.J.H. and D.A.S. and A.Fr. are shareholders in Roche. The other authors declare no competing interests.